In fact, numerous, alternate fusion partners have been documented following the discovery of ALK translocations, for example EML4-ALK-positive non-small-cell lung cancer (NSCLC) and other solid tumours [73,74]. This evidence concerns the gene EML4 and non-small cell lung carcinoma.